• 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
Rycarfa Flavour 20 mg tabletės šunims uždegimui ir skausmui mažinti
Rycarfa Flavour 20 mg tabletės šunims uždegimui ir skausmui mažinti

Rycarfa Flavour tabletės šunims uždegimui ir skausmui mažinti

Prekės kodas: V008488 Gamintojas: KRKA

Šunims uždegimui ir skausmui, sukeltam skeleto ir raumenų, ir degeneracinių sąnarių ligų, mažinti. Pooperaciniam skausmui malšinti, prieš tai naudojus parenterinius vaistus.

0,34 €
Kaina fizinėse parduotuvėse gali skirtis.
Turime sandėlyje. Prekę išsiųsime artimiausią darbo dieną!

Kiekis

Veikliosios medžiagos kiekis

Minimalus prekės užsakymo kiekis yra 10 vnt.

Rycarfa Flavour tabletės šunims uždegimui ir skausmui mažinti

Rycarfa Flavour tabletės šunims uždegimui ir skausmui mažinti

0,34 €

Pristatymas

LP EXPRESS paštomatas

Atsiimkite jums patogiame paštomate.

Pristatysime į namus Trečiadienį, Gruodžio 3 d.
Atsiimti parduotuvėje

Atsiimkite jums patogioje parduotuvėje

Atsiimkite parduotuvėje Antradienį, Gruodžio 2 d.
Venipak paštomatai

Atsiimkite jums patogiame paštomate

Atsiimkite paštomate Trečiadienį, Gruodžio 3 d.
Omniva paštomatai

Atsiimkite jums patogiame paštomate

Atsiimkite paštomate Trečiadienį, Gruodžio 3 d.
Express kurjeris. Greitas pristatymas Vilniaus mieste.

Užsakyk šiandien ir gauk užsakymą rytoj (darbo dienomis)

Pristatysime į namus Antradienį, Gruodžio 2 d.
LP EXPRESS kurjeris

Patogus prekių pristatymas su kurjeriu

Pristatysime į namus Trečiadienį, Gruodžio 3 d.
Venipak kurjeris

Patogus prekių pristatymas su kurjeriu

Pristatysime į namus Trečiadienį, Gruodžio 3 d.
Omniva kurjeris

Patogus prekių pristatymas su kurjeriu

Pristatysime į namus Trečiadienį, Gruodžio 3 d.

Užsakymus nuo 29 € pristatome nemokamai! Iki nemokamo pristatymo trūksta: 28,66 €

* Dėmesio: pristatymo terminai yra preliminarūs ir gali priklausyti nuo kurjerių užimtumo.

Likučiai parduotuvėse

Visada galite užsukti į artimiausią mūsų parduotuvę ir įsigyti norimas prekes. Likučių duomenys atnaujinti prieš 7 val. 54 min.

Atsiliepimai

Apie prekę

Indikacijos

Šunims uždegimui ir skausmui, sukeltam skeleto ir raumenų, ir degeneracinių sąnarių ligų, mažinti. Pooperaciniam skausmui malšinti, prieš tai naudojus parenterinius vaistus.

Kontraindikacijos

  • Negalima naudoti katėms.
  • Negalima naudoti vaikingoms kalėms ir laktacijos metu.
  • Negalima naudoti jaunesniems kaip 4 mėn. amžiaus šuniukams.
  • Negalima naudoti šunims, esant padidėjusiam jautrumui veikliajai (-iosioms) medžiagai (-oms) ar bet kuriai iš pagalbinių medžiagų.
  • Negalima naudoti šunims, sergantiems širdies, kepenų ar inkstų ligomis, jei yra virškinimo trakto opėjimo ar kraujavimo rizika arba jei yra kraujo diskrazijos požymių.

Naudojimas ir dozės

Pradinę 2-4 mg/kg kūno svorio karprofeno paros dozę rekomenduotina skirti kaip vieną dozę arba padalijus į dvi lygias dozes.

Atsižvelgiant į klinikinį atsaką, po 7 dienų paros dozę galima sumažinti iki 2 mg/kg kūno svorio, duodant vieną kartą per parą.

Norint prailginti pooperacinio skausmo malšinimą, parenterinį gydymą injekciniu karprofenu galima tęsti karprofeno tabletėmis, ne ilgiau kaip 5 dienas skiriant 4 mg/kg kūno svorio paros dozę.

Gydymo trukmė priklauso nuo stebimo atsako, tačiau po 14 gydymo dienų šuns būklę iš naujo turi įvertinti veterinarijos gydytojas.

Naudojimas vaikingumo, laktacijos metu

Veterinarinio vaisto saugumas vaikingumo ir laktacijos metu nenustatytas. Negalima naudoti šuningoms kalėms ir laktacijos metu

Specialiosios atsargumo priemonės

Skiriant vaistą senyviems šunims, gali kilti papildomas pavojus. Jei tokio skyrimo negalima išvengti, šunis reikia atidžiai kliniškai stebėti.

Reikia vengti naudoti šunims, kuriems yra dehidracija, hipovolemija ar hipotenzija, nes yra padidėjusio toksinio poveikio inkstams rizika.

NVNU (nesteroidiniai vaistai nuo uždegimo) gali slopinti fagocitozę, todėl uždegimu pasireiškiančių būklių, susijusių su bakterine infekcija, atvejais turi būti pradėtas tinkamas antimikrobinis gydymas. 

Sąveika su kitais vaistais ir kitos sąveikos formos

Negalima vienu metu ar 24 val. po šio vaisto naudojimo naudoti kitų NVNU ir gliukokortikoidų.

Didelė karprofeno dozės dalis jungiasi prie plazmos baltymų ir gali konkuruoti su kitais gerai su baltymais besijungiančiais vaistais, todėl gali pasireikšti toksinis poveikis.

Karprofeno negalima naudoti kartu su vaistais, galinčiais sukelti nefrotoksinį poveikį. 

Šalutinis poveikis

Tipinės su NVNU naudojimu susijusios nepalankios reakcijos yra vėmimas, suminkštėjusios išmatos ar viduriavimas, nematomas kraujas išmatose, apetito sumažėjimas ir letargija. Šios reakcijos paprastai pasireiškia pirmąją gydymo savaitę, dažniausiai yra laikinos bei išnyksta baigus gydymą. Labai retai jos gali būti sunkios ar gyvūnas gali gaišti.

Pasireiškus nepalankioms reakcijoms, būtina nutraukti vaisto naudojimą ir kreiptis patarimo į veterinarijos gydytoją.

Kaip ir kitų NVNU naudojimo atvejais, retai galimos nepalankios inkstų ar idiosinkrazinės kepenų reakcijos.

Gamintojas

KRKA, Slovėnija

Atsisiuntimai

Skirta

Produkto forma
Tabletės

Sudėtis

karprofenas 20 mg / 50 mg / 100 mg

Lorem ipsum dolor sit amet, consectetur adipiscing elit